Changeflow GovPing Pharma & Drug Safety SQZ Biotechnologies Cell Delivery Patent - EP37...
Routine Notice Added Final

SQZ Biotechnologies Cell Delivery Patent - EP3728559A1

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office granted Patent EP3728559A1 to SQZ Biotechnologies Company on April 1, 2026, covering a system for delivering payloads into cells through membrane disruption. The patent names inventors Dadgar, Abdeljawad, and Bernstein and covers 31 designated European states including major markets.

What changed

The EPO published Patent EP3728559A1 granting SQZ Biotechnologies exclusive rights to a cell delivery system that uses mechanical membrane disruption to transport payloads directly into cell cytoplasm. The system represents an alternative to viral vectors and lipid nanoparticles for intracellular delivery.\n\nPharmaceutical and biotech companies developing cell therapies, gene editing tools, or intracellular drug delivery should monitor this IP position. Competitors working on similar delivery technologies may need to design around this patent or seek licenses. The patent applies across all 31 designated EPO member states, providing broad geographic protection in Europe.

What to do next

  1. Monitor patent register for potential licensing opportunities
  2. Review intracellular delivery methods for Freedom to Operate implications
  3. Assess IP landscape for competing cell delivery technologies

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

SYSTEM FOR DELIVERY OF A PAYLOAD INTO A CELL

Publication EP3728559A1 Kind: A1 Apr 01, 2026

Applicants

SQZ Biotechnologies Company

Inventors

DADGAR, Maisam, ABDELJAWAD, Tarek, BERNSTEIN, Howard

IPC Classifications

C12N 5/00 20060101AFI20190628BHEP C12N 15/87 20060101ALI20190628BHEP A61K 35/00 20060101ALI20190628BHEP A61K 48/00 20060101ALI20190628BHEP B82Y 5/00 20110101ALI20190628BHEP C12M 3/06 20060101ALI20190628BHEP G01N 1/31 20060101ALI20190628BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3728559A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Biotech firms
Industry sector
3254.1 Biotechnology
Activity scope
Patent licensing Cell therapy delivery Intracellular drug delivery
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Medical Devices

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.